Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients

Figure 5 Performances of two unsaturated fatty acids with the ability to identify clinically significant fibrosis in nonalcoholic fatty liver disease. A: Serum levels of alpha-octadecatrienoic acid (α-C18:3) in healthy control (HC), type 2 diabetes mellitus (T2DM), no or mild clinically fibrosis with fibrosis 4 score (FIB-4) < 1.3 (F_0-1) and clinically significant fibrosis with FIB-4 ≥ 1.3 (F_2-4) groups; B: Serum levels of γ-linolenic acid (γ-C18:3) in HC, T2DM, F_0-1 and F_2-4 groups; C: Comparison of three clinically significant fibrosis predictive model assessments of the 95%CI on their area under the curve values. Model 1 consists of α-C18:3 and γ-C18:3. Model 2 consists of sex, age, body mass index, systolic blood pressure, duration of diabetes, Triglyceride glucose index, high-density lipoprotein cholesterol, glycosylated hemoglobin, fasting c-peptide, and c-peptide 2 h postprandial. Model 3 was constructed by the factors of model 2 and model 1 together. Wilcoxon test (^aP < 0.05). α-C18:3: Alpha-octadecatrienoic acid; HC: Healthy control; γ-C18:3: γ-linolenic acid; T2DM: Type 2 diabetes mellitus; 95%CI: 95% confidence interval; HC: Healthy control; AUC: Area under the curve; F_0-1: No or mild clinically fibrosis with fibrosis 4 score (FIB-4) < 1.3; F_2-4: Clinically significant fibrosis with FIB-4 ≥ 1.3.